Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.
Adv TherJul 13, 2026 (epub)
Thierry Passeron, Amit G Pandya, Khaled Ezzedine et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2 randomized controlled trial evaluated the efficacy of povorcitinib in 103 adults with extensive nonsegmental vitiligo over 52 weeks. The study found that 34.0% of patients achieved a ≥ 50% reduction in total Vitiligo Area Scoring Index (T-VASI50), while 61.2% achieved a ≥ 50% reduction in facial VASI (F-VASI50) and 45.6% achieved a ≥ 75% reduction (F-VASI75).
Key findings
- 34.0% of patients achieved T-VASI50 at Week 52.
- 61.2% of patients achieved F-VASI50 at Week 52.
- 45.6% of patients achieved F-VASI75 at Week 52.
- Response rates varied by body region, with 57.3% for head and neck.
Why it matters
The findings highlight the potential of povorcitinib to provide significant repigmentation in vitiligo patients across various demographics and body regions, emphasizing the importance of long-term treatment adherence.